Aliases & Classifications for Choroid Disease

MalaCards integrated aliases for Choroid Disease:

Name: Choroid Disease 12 15
Abnormality of the Choroid 29 6
Choroid Diseases 44 73

Classifications:



External Ids:

Disease Ontology 12 DOID:1417
ICD10 33 H31.9 H31 H31.8
ICD9CM 35 363.9
MeSH 44 D015862
NCIt 50 C34468
SNOMED-CT 68 193431000 193480005
UMLS 73 C0008521

Summaries for Choroid Disease

MalaCards based summary : Choroid Disease, also known as abnormality of the choroid, is related to choroideremia and red-green color blindness. An important gene associated with Choroid Disease is CHM (CHM, Rab Escort Protein 1), and among its related pathways/superpathways are RAB geranylgeranylation and Arginine and proline metabolism. The drugs Ranibizumab and Bevacizumab have been mentioned in the context of this disorder. Affiliated tissues include eye, retina and endothelial, and related phenotypes are nervous system and pigmentation

Wikipedia : 76 The choroid, also known as the choroidea or choroid coat, is the vascular layer of the eye, containing... more...

Related Diseases for Choroid Disease

Graphical network of the top 20 diseases related to Choroid Disease:



Diseases related to Choroid Disease

Symptoms & Phenotypes for Choroid Disease

MGI Mouse Phenotypes related to Choroid Disease:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 nervous system MP:0003631 9.76 CHM CNGB3 OAT POU3F4 RAB27A RBP3
2 pigmentation MP:0001186 9.35 CHM OAT RAB27A RPE65 RPGR
3 vision/eye MP:0005391 9.17 CHM CNGB3 OAT RAB27A RBP3 RPE65

Drugs & Therapeutics for Choroid Disease

Drugs for Choroid Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 162)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ranibizumab Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 347396-82-1 459903
2
Bevacizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 216974-75-3
3
Verteporfin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 129497-78-5
4
Iodine Approved, Investigational Phase 4,Not Applicable 7553-56-2 807
5
Povidone Approved Phase 4,Not Applicable 9003-39-8
6
Povidone-iodine Approved Phase 4,Not Applicable 25655-41-8
7
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 50-02-2 5743
8
Triamcinolone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 124-94-7 31307
9
Alfuzosin Approved, Investigational Phase 4 81403-80-7 2092
10
Tamsulosin Approved, Investigational Phase 4 106133-20-4 129211
11
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
12
Ofloxacin Approved Phase 4 82419-36-1 4583
13
Lactitol Investigational Phase 4,Not Applicable 585-86-4 3871
14 Angiogenesis Inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
15 Angiogenesis Modulating Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
16 Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
17 Hormones Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
18 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
19 Dermatologic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
20 cadexomer iodine Phase 4,Not Applicable
21 Antiemetics Phase 4,Phase 3,Phase 2,Not Applicable
22 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
23 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Not Applicable
24 Autonomic Agents Phase 4,Phase 3,Phase 2,Not Applicable
25 BB 1101 Phase 4,Phase 3,Phase 2,Not Applicable
26 Dexamethasone acetate Phase 4,Phase 3,Phase 2,Not Applicable 1177-87-3
27 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
28 glucocorticoids Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
29 HIV Protease Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable
30 Immunosuppressive Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
31 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Not Applicable
32
protease inhibitors Phase 4,Phase 3,Phase 2,Not Applicable
33 triamcinolone acetonide Phase 4,Phase 2,Phase 3,Phase 1
34 Triamcinolone diacetate Phase 4,Phase 2,Phase 3,Phase 1
35 Triamcinolone hexacetonide Phase 4,Phase 2,Phase 3,Phase 1
36 Adrenergic Agents Phase 4
37 Adrenergic alpha-1 Receptor Antagonists Phase 4
38 Adrenergic alpha-Antagonists Phase 4
39 Adrenergic Antagonists Phase 4
40 Neurotransmitter Agents Phase 4
41 Adrenocorticotropic Hormone Phase 4
42 beta-endorphin Phase 4
43 Melanocyte-Stimulating Hormones Phase 4
44 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2
45 Photosensitizing Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
46 Endothelial Growth Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
47 Mitogens Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
48 Ophthalmic Solutions Phase 4,Phase 2
49 Tetrahydrozoline Phase 4,Phase 2
50
Clindamycin Approved, Vet_approved Phase 3 18323-44-9 29029

Interventional clinical trials:

(show top 50) (show all 250)
# Name Status NCT ID Phase Drugs
1 Evaluation of Changes in the Parameters of Optical Coherence Tomography After Intravitreal Injection of Lucentis Unknown status NCT01669447 Phase 4
2 Aflibercept Intravitreal Injection for Myopic Choroidal Neovascularization Unknown status NCT02033018 Phase 4 Aflibercept Injection
3 Ranibizumab for Myopic Neovascularization Unknown status NCT01246089 Phase 4 ranibizumab injection
4 Intravitreal Aflibercept for Neovascular Polypoidal Choroidal Vasculopathy (RIVAL Trial) Unknown status NCT02092532 Phase 4 Rescue Intravitreal Aflibercept Injection
5 The Effects of α-adrenergic Receptor Antagonists on Choroid and Pupil Completed NCT03144596 Phase 4 Alfuzosin Hydrochloride 10 MG;Tamsulosin Hydrochloride 0.4 MG
6 Changes of Macular Pigment and Parameters of Eyes After YAG Laser Treatment in Cases With Capsule Opacification Completed NCT03321253 Phase 4
7 Bevacizumab Intravitreal for Myopic Choroidal Neovascularization Completed NCT00797992 Phase 4 Injection
8 SD-OCT-guided Intravitreal Ranibizumab Treatment in Choroidal Neovascularization Due to Myopia Completed NCT03409250 Phase 4 Ranibizumab, Lucentis
9 Time Course of Activity Signs at SD-OCT High Frequency Intravitreal Ranibizumab Treatment in CNV Due to AMD Completed NCT03393767 Phase 4 Ranibizumab
10 Efficacy Study of Ranibizumab on Patients With Age-related Macular Degeneration. Completed NCT01831947 Phase 4
11 Indocyanine Angiographic Changes of Choroidal Neovascularization by Ranibizumab Completed NCT01810042 Phase 4 ranibizumab
12 Study of H.P. ACTHAR Subcutaneous Gelatin (Gel)(Highly Purified Gel Injection) in Uveitis Patients Completed NCT02764697 Phase 4 H.P. ACTHAR SUBCUTANEOUS GEL INJECTION
13 Macular EpiRetinal Brachytherapy Versus Lucentis® Only Treatment (MERLOT) Completed NCT01006538 Phase 4 Ranibizumab
14 Comparison of Treatment Regimens Using Ranibizumab: Intensive (Resolution of Intra- and Sub-retinal Fluid) vs Relaxed (Resolution of Primarily Intra-retinal Fluid) Treatment. Completed NCT01972789 Phase 4 Ranibizumab
15 Study to Investigate the Safety and Efficacy of Ranibizumab in Patients With Choroidal Neovascularisation Due to Causes Other Than Age Related Macular Degeneration Completed NCT01628354 Phase 4 Ranibizumab
16 Comparison of Safety, Effectiveness and Quality of Life Outcomes Between Labeled Versus "Treat and Extend" Regimen in Turkish Patients With Choroidal Neovascularisation Due to Age-related Macular Degeneration (AMD) Completed NCT01148511 Phase 4 Ranibizumab 0.5 mg
17 Photodynamic Therapy in Occult-Only Lesions (POOL) Completed NCT00135837 Phase 4 Verteporfin for injection
18 Evaluation of Dosing Interval of Higher Doses of Ranibizumab Completed NCT00533520 Phase 4 ranibizumab
19 Reduced Fluence Photodynamic Therapy (PDT) With Visudyne in Combination With Lucentis for Age-Related Macular Degeneration Completed NCT00473642 Phase 4 Ranibizumab;Verteporfin;Verteporfin
20 Safety and Tolerability of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration Completed NCT00504959 Phase 4 ranibizumab
21 Dosing Strategy of Intravitreal Ranibizumab for Pathological Myopia Choroidal Neovascularization Recruiting NCT03042871 Phase 4 0.5mg intravitreal ranibizumab
22 Study of the Effectiveness of Ozurdex for the Control of Uveitis Recruiting NCT02049476 Phase 4 Dexamethasone pellet
23 Efficacy of Aflibercept (Eylea®) on Choroidal Neovascularization (Type 3) Active, not recruiting NCT02320474 Phase 4 Aflibercept
24 An Open Label Trial to Investigate Macugen for the Preservation of Visual Function in Subjects With Neovascular AMD Terminated NCT00327470 Phase 4 Pegaptanib Sodium 0.3 mg
25 Triple Treatment for Detachment of Retinal Pigment Epithelium Secondary to Polypoidal Choroidal Vasculopathy Withdrawn NCT01666236 Phase 4
26 Treatment Of Radiation Retinopathy Trial Unknown status NCT00811200 Phase 2, Phase 3 ranibizumab;triamcinolone acetonide
27 Use of Intravitreal Bevacizumab in Eyes With Choroidal Neovascularization Secondary to Angioid Streaks Unknown status NCT00599820 Phase 3 Intravitreal Bevacizumab
28 Off-Label AVASTIN (BEVACIZUMAB) For Serosanguinous Maculopathy Unknown status NCT00344617 Phase 3 Bevacizumab (tradename: Avastin)
29 A Randomized, Double-blind, Multicenter, Sham-controlled, Safety and Efficacy Study of Conbercept in Patients With mCNV Unknown status NCT01809223 Phase 3 conbercept, Fixed;conbercept, PRN
30 A Study of Strontium90 Beta Radiation With Lucentis to Treat Age-Related Macular Degeneration Unknown status NCT00454389 Phase 3 ranibizumab
31 Double-Masked Study of Photrex (Rostaporfin) Photodynamic Therapy in the Treatment of Age-Related Macular Degeneration Unknown status NCT00157976 Phase 3 Photrex (rostaporfin)
32 Comparative Study With Photodynamic Therapy And Triamcinolone Versus Photodynamic Therapy, Triamcinolone And Ranibizumab In Patients With Subfoveal Choroidal Neovascularization Unknown status NCT00930189 Phase 2, Phase 3 intravitreal injection of ranibizumab;intravitreal injection of triamcinolone
33 Avastin for CNV Secondary to Pattern Dystrophy Unknown status NCT00391144 Phase 2, Phase 3
34 To Compare Intravitreal Clindamycin & Dexamethasone With Classic Treatment of Toxoplasmic Retinochoroiditis Unknown status NCT00372294 Phase 3 pyrimethamine-sulfadiazine + prednisolone;Clindamycin+Dexamethasone
35 Efficacy of Retreatments With Intravitreal Bevacizumab Unknown status NCT00406744 Phase 3 Intravitreal injection of Bevacizumab
36 TTT Versus PDT for Treatment of Choroidal Neovascularization in Age-Related Macular Degeneration Unknown status NCT00260403 Phase 2, Phase 3
37 Macular Photocoagulation Study (MPS) Unknown status NCT00000158 Phase 3
38 Collaborative Ocular Melanoma Study (COMS) Unknown status NCT00000124 Phase 3
39 Intravitreal Bevacizumab for Inflammatory Neovascular Membranes Completed NCT00407121 Phase 3 Bevacizumab
40 Suprachoroidal Injection of CLS-TA in Subjects Non-infectious Uveitis Completed NCT03097315 Phase 3
41 A Controlled, Multi-center Study of the Utilization and Safety of the MK II Inserter and the Safety of the FAI Insert in Subjects With Non-infectious Uveitis Affecting the Posterior Segment of the Eye Completed NCT02748512 Phase 3 FAI insert
42 A Study of LX211 in Clinically Quiescent Non-infectious Intermediate, Anterior and Intermediate, Posterior or Pan-Uveitis Completed NCT00404742 Phase 3 Placebo;LX211;LX211;LX211
43 A Study of LX211 in Active Sight Threatening, Non-infectious Intermediate-, Anterior and Intermediate-, Posterior-, or Pan-Uveitis Completed NCT00404612 Phase 3 Placebo;LX211;LX211;LX211
44 Assess the Efficacy/Safety of Intravitreal Ranibizumab in Patients With Vision Loss Due to Choroidal Neovascularization. Completed NCT01840410 Phase 3 Ranibizumab
45 Multifocal Electrophysiologic Findings After Intravitreal Bevacizumab(Avastin)Treatment Completed NCT00417833 Phase 2, Phase 3 Intravitreal Bevacizumab
46 Effect of Intravitreal Bevacizumab on Non -Age-Related Macular Degeneration (AMD) Related Choroidal Neovascularization (CNV) Completed NCT00370786 Phase 3 bevacizumab
47 A Study of the Safety and Efficacy of a New Treatment for Non-Infectious Intermediate or Posterior Uveitis Completed NCT00333814 Phase 2, Phase 3 Dexamethasone;dexamethasone;Sham injection
48 Myfortic for the Treatment of Non-infectious Intermediate Uveitis Completed NCT01092533 Phase 3 Myfortic;Decortin
49 VEGF Trap-Eye in Choroidal Neovascularization Secondary to Pathologic Myopia (mCNV) Completed NCT01249664 Phase 3
50 Lucentis KAV Study Completed NCT01570608 Phase 3 Ranibizumab;Verteporfin

Search NIH Clinical Center for Choroid Disease

Cochrane evidence based reviews: choroid diseases

Genetic Tests for Choroid Disease

Genetic tests related to Choroid Disease:

# Genetic test Affiliating Genes
1 Abnormality of the Choroid 29

Anatomical Context for Choroid Disease

MalaCards organs/tissues related to Choroid Disease:

41
Eye, Retina, Endothelial, Testes

Publications for Choroid Disease

Articles related to Choroid Disease:

# Title Authors Year
1
ANGIOID STREAKS, AND THEIR RELATION TO A FORM OF CENTRAL CHOROIDAL DISEASE. ( 18168957 )
1931

Variations for Choroid Disease

ClinVar genetic disease variations for Choroid Disease:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 OAT NM_000274.3(OAT): c.875A> G (p.Lys292Arg) single nucleotide variant Likely pathogenic rs1057518927 GRCh38 Chromosome 10, 124402952: 124402952
2 OAT NM_000274.3(OAT): c.875A> G (p.Lys292Arg) single nucleotide variant Likely pathogenic rs1057518927 GRCh37 Chromosome 10, 126091521: 126091521

Expression for Choroid Disease

Search GEO for disease gene expression data for Choroid Disease.

Pathways for Choroid Disease

GO Terms for Choroid Disease

Cellular components related to Choroid Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 photoreceptor outer segment GO:0001750 8.8 CNGB3 RAB27A RPGR

Biological processes related to Choroid Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 intracellular protein transport GO:0006886 9.54 CHM RAB27A RPGR
2 response to stimulus GO:0050896 9.46 CHM CNGB3 RPE65 RPGR
3 retinoid metabolic process GO:0001523 9.32 RBP3 RPE65
4 cellular amino acid biosynthetic process GO:0008652 9.26 OAT PYCR1
5 visual perception GO:0007601 9.1 CHM CNGB3 OAT RBP3 RPE65 RPGR
6 L-proline biosynthetic process GO:0055129 8.96 OAT PYCR1

Sources for Choroid Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....